The stock of Regeneron Pharmaceuticals, Inc (REGN) has seen a 2.03% increase in the past week, with a 1.53% gain in the past month, and a -14.78% decrease in the past quarter. The volatility ratio for the week is 2.13%, and the volatility levels for the past 30 days are at 3.74% for REGN. The simple moving average for the past 20 days is 2.13% for REGN’s stock, with a -25.85% simple moving average for the past 200 days.
Is It Worth Investing in Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Right Now?
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) has a higher price-to-earnings ratio of 15.19x compared to its average ratio. REGN has 36-month beta value of 0.38. Analysts have mixed views on the stock, with 14 analysts rating it as a “buy,” 7 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for REGN is 104.06M, and currently, short sellers hold a 2.77% ratio of that float. The average trading volume of REGN on May 23, 2025 was 1.15M shares.
REGN) stock’s latest price update
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) has seen a decline in its stock price by -1.29 in relation to its previous close of 604.62. However, the company has experienced a 2.03% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-22 that First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors (PI) – carfilzomib or bortezomib – in patients with relapsed/refractory (R/R) multiple myeloma (MM).
Analysts’ Opinion of REGN
Many brokerage firms have already submitted their reports for REGN stocks, with Citigroup repeating the rating for REGN by listing it as a “Buy.” The predicted price for REGN in the upcoming period, according to Citigroup is $700 based on the research report published on May 14, 2025 of the current year 2025.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see REGN reach a price target of $695. The rating they have provided for REGN stocks is “Overweight” according to the report published on April 22nd, 2025.
Leerink Partners gave a rating of “Outperform” to REGN, setting the target price at $834 in the report published on February 05th of the current year.
REGN Trading at -0.61% from the 50-Day Moving Average
After a stumble in the market that brought REGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.72% of loss for the given period.
Volatility was left at 3.74%, however, over the last 30 days, the volatility rate increased by 2.13%, as shares sank -0.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.44% lower at present.
During the last 5 trading sessions, REGN rose by +2.03%, which changed the moving average for the period of 200-days by -44.29% in comparison to the 20-day moving average, which settled at $584.43. In addition, Regeneron Pharmaceuticals, Inc saw -16.21% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REGN starting from McCourt Marion, who sale 1,000 shares at the price of $844.61 back on Nov 01 ’24. After this action, McCourt Marion now owns 12,931 shares of Regeneron Pharmaceuticals, Inc, valued at $844,610 using the latest closing price.
MARION E MCCOURT, the Officer of Regeneron Pharmaceuticals, Inc, proposed sale 1,000 shares at $844.61 during a trade that took place back on Nov 01 ’24, which means that MARION E MCCOURT is holding shares at $844,610 based on the most recent closing price.
Stock Fundamentals for REGN
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.85 for the gross margin
The net margin for Regeneron Pharmaceuticals, Inc stands at 0.32. The total capital return value is set at 0.11. Equity return is now at value 15.96, with 12.51 for asset returns.
Based on Regeneron Pharmaceuticals, Inc (REGN), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 1.46. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 98.59.
Currently, EBITDA for the company is 5.32 billion with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 4.47. The receivables turnover for the company is 2.53for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.93.
Conclusion
To put it simply, Regeneron Pharmaceuticals, Inc (REGN) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
